Compound ID | 1868
Class: Beta-lactam (carbapenem)
| Spectrum of activity: | Gram-negative | 
| Details of activity: | Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets | 
| Description: | Semisynthetic, derived from thienamycin, similar to ertapenem; clinical development only for China | 
| Institute where first reported: | Sihuan Pharmaceutical | 
| Year first mentioned: | 2015 | 
| Highest developmental phase: | Phase 3 (NCT04505683) | 
| Development status: | Active (as of 2022) | 
| Chemical structure(s): | |||||||||||
| 
 | 
 | 
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/58326208 | 
| Guide to Pharmacology: | benapenem | 
| Citation: | https://journals.asm.org/doi/10.1128/AAC.02188-18 |